Tech Company Financing Transactions
Adaptate Biotherapeutics Funding Round
Adaptate Biotherapeutics, based in London, received $18 million from Abingworth and Takeda Ventures.
Transaction Overview
Company Name
Announced On
4/19/2021
Transaction Type
Venture Equity
Amount
$18,000,000
Round
Undisclosed
Investors
Abingworth (Tim Haines)
Proceeds Purpose
The funds will be used to accelerate the progression of Adaptate's therapeutic antibody program towards clinical trials and to expand its internal product pipeline.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
195 Wood Lane WestWorks, White City Place
London, W12 7FQ
UK
London, W12 7FQ
UK
Phone
Website
Email Address
Overview
Adaptate Biotherapeutics is developing therapeutic antibodies which harness the potential of patients' own gamma delta T cells in situ. Gamma delta T cells play a critical role in immune surveillance.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Natalie Mount
Browse more venture capital transactions:
Prev: 4/17/2021: Pearpop venture capital transaction
Next: 4/20/2021: PhenixP2P venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs